NCT06249750RecruitingPhase 2
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
Source: ClinicalTrials.gov · Last updated 8 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 31 Jan 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Pengyuan Liu
- Diseases
- Prostate cancer
- NCT number
- NCT06249750
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From 1 Jan 2024 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those who have recently participated in other clinical trials and have not passed the washout period;
Other illness
- History of malignant tumor other than PC within the past 5 years;
- Accompanied by severe underlying diseases that cannot tolerate this therapy;
- With acute diseases, such as acute infection, active bleeding;
- Those who have a history of allergy to the drugs used in the trial;
Lab values
- Severe abnormalities in the patient's laboratory indices may jeopardize patient safety or compromise this study;
Other
- Those who cannot tolerate systemic heat stress, such as claustrophobic patients;
- Patients with other reasons for not being able to be enrolled in the study, according to the study doctor.
Who the study is looking for
- Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC;
- Complete and reliable medical history and medical records;
- No other primary tumors except CRPC;
- Blood tests, liver function, renal function and electrocardiogram are basically normal;
- Patients with ECOG score 0\~3, aged ≥18 years and \<90 years old;
- Patients with good compliance, able to accept regular follow-up.
Age in the registry: 18 years to 90 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.